{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-006880","form_type":"8-K","ticker":"XTNT","cik":"0001453593","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2023-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.071543+00:00","generated_at":"2026-06-18T09:36:54.159556+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Xtant Medical Q4 revenue up 9% to $15.3M; full year net loss widens to $8.5M","bullets":["Q4 revenue $15.3M, up 9% YoY; full year revenue $58.0M, up 5% YoY.","Q4 net loss $2.2M ($0.02 per share), vs $2.3M ($0.03) in prior year.","Full year net loss $8.5M ($0.09 per share), up from $4.8M ($0.06) in 2021.","Non-GAAP Adjusted EBITDA full year loss $3.0M vs gain $0.3M in 2021.","Acquired Coflex product line to enhance fixation offering; financial details not disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-006880","json":"https://secwatch.observer/filing/0001493152-23-006880.json","markdown":"https://secwatch.observer/filing/0001493152-23-006880.md","text":"https://secwatch.observer/filing/0001493152-23-006880.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223006880/0001493152-23-006880-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223006880/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T09:36:54.159556+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4de82a18256326d75c122e7f73065d5e9cb00a1b","claim":"Xtant Medical Holdings, Inc. reported the fourth quarter and year ended December 31, 2022 results: revenue $15.3 million, net income $0.02 per share, EPS $0.02 per share.","evidence_excerpt":"network, all of which are core focus areas to our long-term growth strategy.” Fourth Quarter and Full Year 2022 Financial Results Fourth quarter 2022 revenue grew 9% to $15.3 million, compared to $14.0 million for the same quarter in 2021. Full year 2022 revenue was $58.0 million, compared to $55.3 million for 2021. The increase in revenue was largely","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223006880/0001493152-23-006880-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2022"},{"label":"Revenue","value":"$15.3 million"},{"label":"Net income","value":"$0.02 per share"},{"label":"EPS","value":"$0.02 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}